Floatz logo

Pitolisant

Excessive Daytime Sleepiness

BioprojetSmall moleculePhase 3Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Excessive Daytime Sleepiness cohort.

Asset / SponsorPhaseRating
Modafinil
Bioprojet
Phase 3BB
bf2.649
Bioprojet
Phase 2B
Ben-2001
BenevolentAI Bio
Phase 2B
MIRTAZAPINE
University Health Network, Toronto
Phase 2B

Same molecule, other indications

Pitolisant is also rated in:

narcolepsyDormant
BB
Indicative ·
68 / 100
View asset →
narcolepsy-cataplexy syndromeDormant
BB
Indicative ·
68 / 100
View asset →
Parkinson diseaseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →